Hard to Treat Diseases, Inc. (HTDS)

[mickymoose99]

.Hard to Treat Diseases, Inc. (HTDS) Targets Merger with Biotechnology Company
.
Companies:Hard to Treat Diseases Inc..Related Quotes
Symbol Price Change
HTDS.PK 0.0006 +0.0001


{"s" : "htds.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Hard to Treat Diseases, Inc. On Friday November 12, 2010, 4:01 pm EST
SHENZEN, CHINA--(Marketwire - 11/12/10) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS - News) (Welcome to HTDS Medical) is targeting a merger with a Canadian biotechnology company that deals with blood transfusion products.

This biotechnology company, who wishes to remain anonymous at this stage of negotiations, is a biotechnology company that is involved in validating a product that will reduce the major side effects related to transfusions of donated blood or hemoglobin based blood substitutes. The market value for blood transfusions on the North American market is currently in excess of $14 billion USD.

There is currently a shortfall of blood available for transfusions. Serious harmful side effects exist in the use of stored donor blood; specifically, the loss of Nitric Oxide (NO) from the recipients' blood creates a hazardous condition known as vasoconstriction. Due to the demand for blood and associated transfusions, there are an increasing number of clinical trials and process being developed to counteract the loss of NO from blood.

This up-and-coming biotech company plans to demonstrate in pre-clinical tests that its product can circumvent the loss of NO from blood and improve the shelf life of stored blood for up to 42 days.

HTDS has remained silent for the past several months as it worked on this deal is pleased with this merger opportunity and feels that it may be a perfect fit alongside their current medical subsidiaries Shenzhen Mellow Hope Pharm Industrial Co., Ltd. and Slavica Biochem.

HTDS expects to be in a position to release the name of the merger candidate and the new appointee officers and all relevant data shortly. The company is of the opinion that this is a significant event that requires a public release.

More details to follow shortly.

About Mina Mar Group:

Mina Mar Group pioneered the "Go Public Free" program, the first firm to challenge the short sellers, stock bashers and repeal of the "Communication Decency Act". Visit www.minamargroup.com/ice to learn more.

Mina Mar Marketing Group, MMMG (Investor relations firm offering a complete range of Investor relations services and consulting) offers publicly traded companies a full array of services such as Investor Relations and maintenance investor awareness.

To be included in company's email database for press releases, "Friday Tips", industry updates, and company activity that may or may not be news released, please subscribe for opt-in mailer at MinaMarGroup - International financial consulting firm and reverse merger transaction specialists..

[mickymoose99]

Mellow Hope (HTDS) Delivers First Batch of BIOVAC-FLU Samples to India
.
Companies:Hard to Treat Diseases Inc..Related Quotes
Symbol Price Change
HTDS.PK 0.00 0.00


{"s" : "htds.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Hard to Treat Diseases, Inc. On Friday November 19, 2010, 4:01 pm EST
SHENZHEN, CHINA--(Marketwire - 11/19/10) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS - News) (Welcome to HTDS Medical) subsidiary Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) has delivered its first BIOVAC-FLU samples to India.

Mellow Hope (Shenzhen Mellow Hope Pharm Industrial Co., Ltd.), the biggest exporter of biological vaccines in China, has delivered a batch of Influenza virus vaccines, Inactivated (Split) (BIOVAC-FLU) to a company in India for sample analysis before beginning the new purchase order. The company expects to finalize the sample analysis within one month. After that a new purchase order will be signed between Mellow Hope and the partner in India. That is the first batch of BIOVAC-FLU exported to India in 2010.

Mellow Hope is pleased with this agreement and hopes that this will provide new opportunities for growth

[mickymoose99]

Originally Posted by sarahwilliams

I know you've heard of it everyday but you should definitely try this! A newsletter proven and approved by many!

Subscribed HERE

I Agree sarah we do hear it everyday and me for one is getting tired of it and we wish you would stop posting over our post

[mickymoose99]

Hard to Treat Diseases, Inc. (HTDS) Releases the Name of Its Biotechnology Merger Candidate
.
Companies:HARD TO TREAT DISEAS.Related Quotes
Symbol Price Change
HTDS.PK 0.00 +0.00


{"s" : "htds.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Hard to Treat Diseases, Inc. On Monday November 22, 2010, 1:30 pm
SHENZHEN, CHINA--(Marketwire - 11/22/10) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS - News) (Welcome to HTDS Medical) announces that the merger negotiations with the Canadian Biotechnology company are proceeding well, and that the merger candidate permitted HTDS to release the name and additional information about the candidate:

The merger candidate, Hb Products Inc., is a Canadian biotechnology company that deals with blood transfusion products. Hb Products Inc. is a biotechnology company that is involved in validating a product that will reduce the major side effects related to transfusions of donated blood or hemoglobin-based blood substitutes.

Hb Products Inc. focuses on treatment of serious harmful side effects existing with the use of stored donor blood, focusing specifically on solving the loss of Nitric Oxide (NO) from the recipients' blood, which creates a hazardous condition called vasoconstriction. The market for these blood products is relatively untapped and highly competitive. Due to the potential market for blood substitutes and the shortfall of available donor blood, several pharmaceutical companies have attempted to gain FDA approval for their products, but none have succeeded as of yet. Hb Products Inc. plans to demonstrate in pre-clinical tests that its product can circumvent the loss of NO from blood and improve the shelf life of stored blood for up to 42 days.

The market value for blood transfusions on the North American market is currently in excess of $14 billion USD.

HTDS sees Hb Products as a perfect fit alongside their current medical subsidiaries Shenzhen Mellow Hope Pharm Industrial Co., Ltd. and Slavica Biochem.

[mickymoose99]

.Mellow Hope (HTDS) Registration Certificate of Cognistar Approved in India
.
Companies:HARD TO TREAT DISEAS.Related Quotes
Symbol Price Change
HTDS.PK 0.00 0.00


{"s" : "htds.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Hard to Treat Diseases, Inc. On Friday November 26, 2010, 3:45 pm EST
SHENZHEN, CHINA--(Marketwire - 11/26/10) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS - News) (Welcome to HTDS Medical) subsidiary Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) announces that, after four years of continuous effort, the registration of Cerebroprotein Hydrolysate for Injection (Cognistar) has been approved by India's drug regulator, Drugs Controller General of India (DCGI).

As soon as the approval is finalized, Mellow Hope (Shenzhen Mellow Hope Pharm Industrial Co., Ltd.) will launch this product in the local market. Until this point there has been no local supplier in India for Cognistar, so the company anticipates healthy sales as it fills this market vacancy and claims a large market share. The company received permit to import this product to India, and copy of this certificate will be made available @ Welcome to HTDS Medical. The company will also post this certificate on OTCMarkets.Com as a filing shortly.

Cognistar is a unique nutriment for the brain. It regulates and improves nerve cell metabolism, promotes synapse generation, induces nerve cell differentiation, and protects nerve cells against damages by ischemia and neurotoxins.

The company is pleased at this approval after years of diligent research, and will keep the investor public updated as the first batches of Cognistar reach the Indian market.

In other company news and updates, regarding the news of November 22, 2010 and merger progress with a Canadian based Hb Products Inc. (Hb) the company is working diligently and vigorously to have the merger completed way ahead of the Christmas holidays. Currently a new updated web site is being developed to include Hb with a preview available at this link Welcome to HTDS Medical.

The management will release further updates shortly as they become available.

[sarahpeterson]

Hi, we offer excellent service when it comes to stock pickings. Subscribe and check it out yourself.

Subscribed HERE